182 related articles for article (PubMed ID: 12462283)
1. The abacavir hypersensitivity reaction: a review.
Clay PG
Clin Ther; 2002 Oct; 24(10):1502-14. PubMed ID: 12462283
[TBL] [Abstract][Full Text] [Related]
2. Incidence of abacavir hypersensitivity reactions in euroSIDA.
Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
[TBL] [Abstract][Full Text] [Related]
3. Abacavir pharmacogenetics--from initial reports to standard of care.
Martin MA; Kroetz DL
Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
[TBL] [Abstract][Full Text] [Related]
4. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
James JS
AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
[TBL] [Abstract][Full Text] [Related]
6. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
Wit FW; Wood R; Horban A; Beniowski M; Schmidt RE; Gray G; Lazzarin A; Lafeuillade A; Paes D; Carlier H; van Weert L; de Vries C; van Leeuwen R; Lange JM
AIDS; 2001 Dec; 15(18):2423-9. PubMed ID: 11740193
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Castillo SA; Hernandez JE; Brothers CH
Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
[TBL] [Abstract][Full Text] [Related]
8. Once-daily abacavir in place of twice-daily administration.
Goedken AM; Herman RA
Ann Pharmacother; 2005; 39(7-8):1302-8. PubMed ID: 15956231
[TBL] [Abstract][Full Text] [Related]
9. Abacavir hypersensitivity reaction: an update.
Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE
Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141
[TBL] [Abstract][Full Text] [Related]
10. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
Bellagamba R; Tommasi C; De Marco M; Narciso P
J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
[No Abstract] [Full Text] [Related]
11. Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany.
Wolf E; Blankenburg M; Bogner JR; Becker W; Gorriahn D; Mueller MC; Jaeger H; Welte R; Baudewig M; Walli R; Stoll M
Eur J Med Res; 2010 Apr; 15(4):145-51. PubMed ID: 20554495
[TBL] [Abstract][Full Text] [Related]
12. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
13. Low frequency of hypersensitivity reactions to abacavir in HIV infected patients in a referral center in Bahia, Brazil.
Barreto RG; Brites C
Braz J Infect Dis; 2019; 23(4):268-270. PubMed ID: 31374183
[TBL] [Abstract][Full Text] [Related]
14. Detection of abacavir hypersensitivity by ELISpot method.
Esser S; Jablonka R; Heinemann FM; Reuter S; Jaeger H; von Krosigk A; Schenk-Westkamp P; Schadendorf D; Horn PA; Lindemann M
Inflamm Allergy Drug Targets; 2012 Jun; 11(3):227-34. PubMed ID: 22338581
[TBL] [Abstract][Full Text] [Related]
15. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
[TBL] [Abstract][Full Text] [Related]
16. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A
Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242
[TBL] [Abstract][Full Text] [Related]
17. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
[TBL] [Abstract][Full Text] [Related]
18. Abacavir.
Foster RH; Faulds D
Drugs; 1998 May; 55(5):729-36; discussion 737-8. PubMed ID: 9585869
[TBL] [Abstract][Full Text] [Related]
19. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
[TBL] [Abstract][Full Text] [Related]
20. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
Frissen PH; de Vries J; Weigel HM; Brinkman K
AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
